Although PPARβ/δ agonists may not be beneficial for clinical use to treat type II diabetes or dyslipidemia, considering the risks when administered systemically [26], PPARβ/δ administration for musculoskeletal applications, such as the promotion of osteogenesis for fracture healing and the induction of MSC differentiation to chondrocytes to promote cartilage regeneration, is appealing. This evidence concerns the gene PPARD and type 2 diabetes mellitus.